tadalafil   Click here for help

GtoPdb Ligand ID: 7299

Synonyms: Adcirca® | Cialis® | IC-351 | IC351
Approved drug PDB Ligand
tadalafil is an approved drug (EMA (2002), FDA (2003))
Compound class: Synthetic organic
Comment: Tadafil is a phosphodiesterase type 5 (PDE5) inhibitor.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tadalafil

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 74.87
Molecular weight 389.14
XLogP 1.75
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1N(C)CC(=O)N2C1Cc1c(C2c2ccc3c(c2)OCO3)[nH]c2c1cccc2
Isomeric SMILES O=C1N(C)CC(=O)N2[C@@H]1Cc1c([C@H]2c2ccc3c(c2)OCO3)[nH]c2c1cccc2
InChI InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1
InChI Key WOXKDUGGOYFFRN-IIBYNOLFSA-N
No information available.
Summary of Clinical Use Click here for help
Used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension. The drug used to treat ED and BPH is approved as Cialis, and the drug approved for pulmonary arterial hypertension is Adcirca. Approvals for different indications have separate approval dates.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Such inhibitors block the degradative action of PDE5 on cGMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. This action dilates these blood vessels allowing blood ingress and leads to functional erection. Vasoconstriction in the pulmonary vascular lumen causes PAH and tadalafil can also effect vasodilation in these vessels, thus reducing pulmonary arterial pressure. Due to its extended elimination half-life compared to other PDE5 inhibitors [1], this drug is useful for once-a-day dosing for patients with pulmonary arterial hypertension.
External links Click here for help